- Pendahuluan
- Farmakologi
- Formulasi
- Indikasi dan Dosis
- Efek Samping dan Interaksi Obat
- Penggunaan pada Kehamilan dan Ibu Menyusui
- Kontraindikasi dan Peringatan
- Pengawasan Klinis
Formulasi Pioglitazone
Formulasi pioglitazone tersedia dalam bentuk tablet. Pioglitazone dapat diminum peroral dengan/tanpa makanan.[7,8]
Bentuk Sediaan
Sediaan pioglitazone terdiri dari tablet oral, dengan dosis 15 mg, 30 mg, dan 45 mg, untuk terapi diabetes melitus tipe 2.[8]
Referensi
7. National Center for Biotechnology Information. PubChem Compound Summary for CID 60560, Pioglitazone hydrochloride. 2023. https://pubchem.ncbi.nlm.nih.gov/compound/Pioglitazone-hydrochloride..
8. FDA. ACTOS™ (Pioglitazone Hydrochloride) Tablets. Highlights of Prescribing Information, 1999. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf
10. Pendsey SP , Dhanvijay VP , Joshi PP . Efficacy of Pioglitazone as an add on drug with insulin, glibenclamide and metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetologica Croatica, 2002; 31:51-57.
18. Rosenstock J, Einhorn D, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo controlled study in patients receiving stable insulin therapy. Int 41J Clin Pract 2002 May; 56 (4): 251-7
19. Einhorn D, Rendell M, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000 Dec; 22 (12): 1395-409
20. Matthews DR, Charbonnel BH, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21 (2): 167-74
21. Mattoo V, Eckland D, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. ClinTher 2005 May; 27 (5): 554-67
22. Kipnes MS, Krosnick A, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus:a randomized, placebo-controlled study. Am J Med 2001 Jul; Ali111 (1): 10-7
23. Charbonnel B, Schernthaner G, et al. Long-term glycaemia efficacy and tolerability of add-on pioglitazone therapy to 2failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 May 12; 48: 1093-104
24. Yamanouchi T. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Vascular health and risk management, 2010. 6, 189–197. https://doi.org/10.2147/vhrm.s5838
25. Fernandez M, Triplitt C, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care. 2008;31(1):121–127
(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)